glp-1 who should not take Why do patients stop drugs? GLP-1 nausea: How to handle

Eli Lillys oral GLP-1 candidate orforglipron met all primary and secondary endpoints in a Phase 3 study of adults with type 2 diabetes, the

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Experts warn that misuse of Ozempic and Mounjaro could trigger serious health risks without medical supervision.

While pharmaceutical GLP-1 receptor agonists are widely used, increasing evidence suppor

Learn how GLP-1 agonists impact weight loss, metabolism, & cognitive health

(2023) conducted a meta-analysis of existing systematic reviews and confirmed ginger's traditional role in supporting digestive comfort